ArticleDiscover oncology2026
Identification of a novel platelet-related prognostic model for hepatocellular carcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) is a highly lethal malignancy with high invasiveness and metastasis. Despite progress in its treatment, the high mortality rate persists due to poor prognosis. In this study, we aimed to develop a prognostic model for HCC using platelet-related genes. We downloaded and preprocessed data from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Through differential gene expression analysis, univariate Cox regression, Least absolute shrinkage and selection operator (LASSO) machine learning, and multivariate Cox regression, we constructed a prognostic model consisting of six genes (KIF18A, HRG, TUBA4B, MAFF, SELP, and IGF1). The survival analysis and ROC curve evaluation conducted on both the training and validation sets showed excellent predictive performance of the model. In addition, the model was also associated with the malignancy and risk of metastasis of tumors. Additionally, analysis of half maximal inhibitory concentration (IC50) values between high- and low-risk groups for various drugs showed significant differences, suggesting potential differences in predicted drug sensitivity between risk groups. We identified potential stem-like cell subpopulations in HCC cells, which are mostly in the late stage of malignant cell differentiation. In conclusion, we successfully constructed a novel platelet-related prognostic model for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.